<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01131689</url>
  </required_header>
  <id_info>
    <org_study_id>2008-10-009</org_study_id>
    <nct_id>NCT01131689</nct_id>
  </id_info>
  <brief_title>Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase 1 Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed&#xD;
      synergistic effect to sorafenib in human colon carcinoma cell lines. Therefore, sorafenib&#xD;
      combined with S-1 might be more effective treatment for patients with advanced HCC than&#xD;
      sorafenib monotherapy. The investigators propose to conduct a phase I study to determine&#xD;
      maximal tolerated dose (MTD) of S-1 in combination with fixed dose of sorafenib in patients&#xD;
      with advanced HCC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>1 year</time_frame>
    <description>Primary objectives:&#xD;
1. To determine maximal tolerated dose (MTD) of S-1 combined with fixed dose of sorafenib 400mg twice daily.&#xD;
Secondary objectives:&#xD;
1. To evaluate toxicity profiles and dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib, TS-1</intervention_name>
    <description>D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed hepatocellular carcinoma (HCC) or a combination&#xD;
             of radiologically compatible finding to HCC, alpha-fetoprotein&gt;400ng/mL and liver&#xD;
             cirrhosis&#xD;
&#xD;
          2. Inoperable disease as defined by&#xD;
&#xD;
               1. Localized disease in a portion of the liver that doses not allow the possibility&#xD;
                  of complete surgical removal of the tumor with a clear resection margin OR&#xD;
&#xD;
               2. Presence of extra-hepatic disease OR&#xD;
&#xD;
               3. Main portal vein or hepatic vein involvement (invasion or tumor thrombus) OR&#xD;
&#xD;
               4. The HCC must not be amenable to intra-arterial therapy or local ablative therapy&#xD;
&#xD;
          3. Minimum life expectancy of 12 weeks&#xD;
&#xD;
          4. Age&gt;18 years.&#xD;
&#xD;
          5. ECOG Performance Status of 0-1&#xD;
&#xD;
          6. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to screening:&#xD;
&#xD;
               1. Hemoglobin&gt;9.0 g/dl&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) &gt;1,500/mm3&#xD;
&#xD;
               3. Platelet count &gt; 75,000/Î¼l&#xD;
&#xD;
               4. Total bilirubin &lt; 1.5 times the upper limit of normal&#xD;
&#xD;
               5. ALT and AST &lt;5 x upper limit of normal&#xD;
&#xD;
               6. Albumin &gt;= 3g/dL&#xD;
&#xD;
               7. PT-INR/PTT &lt;1.5 x upper limit of normal&#xD;
&#xD;
               8. Serum creatinine &lt; 1.5 x upper limit of normal or Creatinine clearance &gt;=50mL/min&#xD;
&#xD;
          7. Signed and dated informed consent before the start of specific protocol procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Decompensated cirrhosis or stage C according to the Child-Pugh Classification&#xD;
&#xD;
          2. Chemo-embolization within 8 weeks of inclusion&#xD;
&#xD;
          3. Other concomitant anticancer agent, including Tamoxifen and Interferon&#xD;
&#xD;
          4. History of cardiac disease: congestive heart failure &gt;NYHA class 2; active CAD (MI&#xD;
             more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring&#xD;
             anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          5. History of HIV infection&#xD;
&#xD;
          6. Active clinically serious infections (&gt; grade 2 CTCAE version 3.0)&#xD;
&#xD;
          7. Symptomatic metastatic brain or meningeal tumors&#xD;
&#xD;
          8. Patients with seizure disorder requiring medication (such as steroids or&#xD;
             anti-epileptics)&#xD;
&#xD;
          9. History of organ allograft&#xD;
&#xD;
         10. Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
         11. Patients undergoing renal dialysis&#xD;
&#xD;
         12. Radiotherapy during study or within 4 weeks of start of study drug.&#xD;
&#xD;
         13. Major surgery within 4 weeks of start of study&#xD;
&#xD;
         14. Autologous bone marrow transplant or stem cell rescue within 4 months of study&#xD;
&#xD;
         15. Prior exposure to the study drug.&#xD;
&#xD;
         16. Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed within 7 days of the start of treatment. Both men&#xD;
             and women enrolled in this trial must use adequate barrier birth control measures&#xD;
             during the course of the trial (and men for at least 3 months after last&#xD;
             administration of study medication).&#xD;
&#xD;
         17. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
         18. Any condition that is unstable or could jeopardize the safety of the patient and their&#xD;
             compliance in the study&#xD;
&#xD;
         19. Patients unable to swallow oral medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>May 25, 2010</study_first_submitted>
  <study_first_submitted_qc>May 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2010</study_first_posted>
  <last_update_submitted>January 31, 2012</last_update_submitted>
  <last_update_submitted_qc>January 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

